Müllerian Adenosarcoma Diagnosis via Genetic Markers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic and treatment methods for Müllerian Adenosarcoma lack reliable molecular and genetic markers, making it difficult to distinguish from similar tumors and predict the risk of sarcomatous overgrowth, which affects prognosis and treatment planning.
Innovation Solution
Detecting specific genetic abnormalities such as mutations in the ATRX gene and copy number variations in MYBL1, MDM2, HMGA2, and CDK4 genes using assays like fluorescent in-situ hybridization and immunohistochemistry to diagnose and predict the risk of Müllerian Adenosarcoma and guide treatment decisions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If histologic examination alone is used for diagnosis, then the diagnostic process is simple, but the diagnostic accuracy is insufficient due to inability to reliably distinguish MA from similar tumors
Solution Approach 1:
The patent introduces molecular markers (ATRX mutation status, MYBL1/MDM2/HMGA2/CDK4 copy number variations) as intermediary elements that mediate between the tumor tissue and the diagnostic conclusion. These molecular markers serve as objective indicators that resolve the ambiguity in histologic diagnosis, enabling reliable distinction between MA and similar tumors without requiring complex multi-step diagnostic algorithms
Solution Approach 2:
The patent replaces the purely morphological/mechanical examination approach (histologic visualization and subjective interpretation) with molecular biological detection methods (immunohistochemistry, fluorescent in-situ hybridization, polymerase chain reaction). This substitution provides objective, quantifiable molecular data that supersedes the limitations of subjective histologic assessment
2Reliability
If no molecular markers are used, then the diagnostic method is simple and quick, but the ability to predict sarcomatous overgrowth risk is lacking
Solution Approach 1:
The patent performs molecular marker detection (ATRX mutation, MYBL1/MDM2/HMGA2/CDK4 copy number) as a preliminary action during the diagnostic phase, before treatment planning. This advance detection of prognostic indicators allows clinicians to predict sarcomatous overgrowth risk beforehand, enabling proactive adjustment of treatment strategies rather than reactive changes based on later clinical progression
Solution Approach 2:
The patent changes the diagnostic parameters from purely morphological features (cellular arrangement, nuclear atypia) to include molecular parameters (ATRX expression status, copy number variations). This parameter expansion provides new dimensions of information that correlate with biological behavior and prognosis, enabling more reliable risk stratification
3Adaptability or versatility
If treatment is based on histology alone, then treatment planning is straightforward, but the personalization of treatment is insufficient
Solution Approach 1:
The patent applies the principle of local quality by tailoring treatment to the specific molecular characteristics of each patient's tumor. Rather than uniform treatment protocols, the detection of ATRX mutations and MYBL1/MDM2/HMGA2/CDK4 copy number variations identifies distinct molecular subtypes that receive customized treatment approaches, optimizing therapy for each patient's specific tumor biology
Solution Approach 2:
The patent implements feedback by using molecular marker results to guide and adjust treatment decisions. The detection data feeds back into the clinical decision-making process, allowing treatment plans to be adapted based on the specific molecular profile detected, creating a closed-loop system where diagnosis informs treatment which can be refined based on molecular findings
Data Source
AI summary
Methods for diagnosing and treating Müllerian Adenosarcoma that include detecting the presence of one or more of a mutation in an ATRX gene, and/or a Copy Number Variation (CNV) in a MYBL1, MDM2, HMGA2, and/or CDK4 gene.